Table 2.
SARS-CoV-2 vaccination coverage between people with and without HIV.
| Total | PWH | PWoH | p-Value | |
|---|---|---|---|---|
| Primary vaccination | n (%) | n (%) | n (%) | <0.001 |
| Unvaccinated | 29,606 (14.7) | 3343 (18.2) | 26,263 (14.3) | |
| Incomplete | 7835 (3.9) | 652 (3.6) | 7183 (3.9) | |
| Complete | 164,189 (81.4) | 14,335 (78.2) | 149,854 (81.8) | |
| Primary vaccination type | <0.001 | |||
| BNT162 | 105,743 (61.5) | 7924 (52.9) | 97,819 (62.3) | |
| ChAdOx1-S | 16,668 (9.7) | 1436 (9.6) | 15,232 (9.7) | |
| mRNA-1273 | 29,505 (17.2) | 3737 (24.9) | 25,768 (16.4) | |
| Ad26.COV2.S | 13,346 (7.8) | 1321 (8.8) | 12,025 (7.7) | |
| Combined | 6762 (3.9) | 569 (3.8) | 6193 (3.9) | |
| Booster doses | <0.001 | |||
| Yes | 104,332 (63.5) | 9823 (68.5) | 94,509 (63.1) | |
| No | 59,857 (36.5) | 4512 (31.5) | 55,345 (36.9) | |
| Booster doses type | <0.001 | |||
| BNT162 | 13,973 (13.4) | 1413 (14.4) | 12,560 (13.3) | |
| ChAdOx1-S | 26 (0) | 4 (0) | 22 (0) | |
| mRNA-1273 | 90,250 (86.5) | 8372 (85.2) | 81,878 (86.6) | |
| Ad26.COV2.S | 10 (0) | 2 (0) | 8 (0) | |
| Combined | 40 (0) | 17 (0.2) | 23 (0) | |
| Other | 33 (0) | 15 (0.2) | 18 (0) | |
| Median time between primary and booster dose, months (IQR) | 6.44 (5.98–7.1) | 6.44 (5.92–7.13) | 6.44 (6.02–7.1) | <0.001 |
Abbreviations: PWH, people with HIV; PWoH, people without HIV; IQR, interquaartile range.